Learn about Bet
- Bet
- Bet-story
Before KRYSTEXXA with methotrexate

REAL PATIENT
Patient name/age:
Bet, 43
Occupation:
Stay-at-home parent
Patient History
- A father and husband who loves spending time with his children
- Has had gout for over 20 years
- Stopped working construction due to pain and limited mobility
- No known comorbidities
ACR, American College of Rheumatology; sUA, serum uric acid.
sUA:
>6 mg/dL
BMI:
38.5
Tophi:
Visible Tophi
Swollen/tender joints:
Chronic pain in multiple joints
Flares:
>2/year
Allopurinol:
7 years with increasing doses
Febuxostat:
1 year
Colchicine:
7 years while flaring
The ACR Guidelines STRONGLY RECOMMEND pegloticase for patients like Bet1
KRYSTEXXA can be co-administered with methotrexate2
ACR, American College of Rheumatology; sUA, serum uric acid.
After KRYSTEXXA with methotrexate

REAL PATIENT
Patient name/age:
Bet, 43
Occupation:
Stay-at-home parent
“I wish I had started KRYSTEXXA (with methotrexate) sooner. Now, I go out and do things and not just want to stay at home. I’m definitely in a better place now.”
INDICATION
KRYSTEXXA (pegloticase) is indicated for the treatment of chronic gout in adult patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.
ACR, American College of Rheumatology; sUA, serum uric acid.
sUA:
<1 mg/dL
Tophi:
Reduced
Functional status:
Can walk and perform daily activities
Swollen/tender joints:
Chronic pain in multiple joints
BMI:
41.1
Colchicine:
0.6 mg as needed
KRYSTEXXA:
8 mg every two weeks
Methotrexate:
15 mg orally per week
The ACR Guidelines STRONGLY RECOMMEND pegloticase for patients like Bet1
KRYSTEXXA can be co-administered with methotrexate2
ACR, American College of Rheumatology; sUA, serum uric acid.